EUVIMEDEUVIMED entdecken
Open Access

Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma

Giuseppe Tarantino iD, Cora A Ricker iD, Annette Wang, William Ge iD, Tyler J Aprati iD, Amy Y Huang iD, Shariq Madha iD, Jiajia Chen, Yingxiao Shi, Marc Glettig iD, Catherine H Feng iD, Dennie T Frederick und 27 weitere

Science Advances · 29.11.2024 · 10 (48)

DOI: 10.1126/sciadv.adp4670 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 29.11.2024. Verfasst von Giuseppe Tarantino und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston MA, USA. Hauptthemen laut MEDLINE: Melanoma, Drug Resistance, Neoplasm, Immune Checkpoint Inhibitors, Ploidies. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The introduction of immune checkpoint blockade (ICB) has markedly improved outcomes for advanced melanoma. However, many patients develop resistance through unknown mechanisms. While combination ICB has improved response rate and progression-free survival, it substantially increases toxicity. Biomarkers to distinguish patients who would benefit from combination therapy versus aPD-1 remain elusive. We analyzed whole-exome sequencing of pretreatment tumors from four cohorts ( n = 140) of ICB-naïve patients treated with aPD-1. High genomic heterogeneity and low ploidy robustly identified patients intrinsically resistant to aPD-1. To establish clinically actionable predictions, we optimized and validated a predictive model using ploidy and heterogeneity to confidently identify (90% PPV) patients with intrinsic resistance to and worse survival on aPD-1. We further observed that three of seven (43%) patients predicted to be intrinsically resistant to single-agent PD-1 ICB responded to combination ICB, suggesting that these patients may benefit disproportionately from combination ICB. These findings highlight the importance of heterogeneity and ploidy, nominating an approach toward clinical actionability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaDrug Resistance, NeoplasmImmune Checkpoint InhibitorsPloidiesProgrammed Cell Death 1 ReceptorHumansGenetic HeterogeneityFemaleExome SequencingNeoplasm MetastasisGenomicsMaleBiomarkers, TumorMiddle Aged

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPDCD1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston MA, USA.
  • Harvard Medical School, Boston, MA, USA.
  • Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Computational and Systems Biology Program, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Worcester Polytechnic Institute, Worcester, MA, USA.
  • Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.

ORCID-Profile: Giuseppe Tarantino, Cora A Ricker, William Ge, Tyler J Aprati, Amy Y Huang, Shariq Madha, Marc Glettig, Catherine H Feng, Samuel Freeman, Michael P Manos, Lisa Zimmer, Jacob C Jameson, Soroush Saghafian, Luc G T Morris, Brendan Reardon, Bastian Schilling, Anita Giobbie-Hurder, Natalie I Vokes, Keith T Flaherty, Catherine J Wu, Genevieve M Boland, F Stephen Hodi, Eliezer M Van Allen, Dirk Schadendorf, David Liu

Förderung

  • NCI NIH HHS
  • NIMH NIH HHS

Zitieren

APA

Tarantino, G., Ricker, C. A., Wang, A., Ge, W., Aprati, T. J., Huang, A. Y., Madha, S., Chen, J., Shi, Y., Glettig, M., Feng, C. H., Frederick, D. T., Freeman, S., Holovatska, M. M., Manos, M. P., Zimmer, L., Rösch, A., Zaremba, A., Livingstone, E., …, & Liu, D. (2024). Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma. Science Advances, 10(48). https://doi.org/10.1126/sciadv.adp4670

Vancouver

Tarantino G, Ricker CA, Wang A, Ge W, Aprati TJ, Huang AY, et al. Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma. Science Advances. 2024;10(48). doi:10.1126/sciadv.adp4670

BibTeX
@article{Tarantino2024,
  author = {Tarantino, Giuseppe and Ricker, Cora A and Wang, Annette and Ge, William and Aprati, Tyler J and Huang, Amy Y and Madha, Shariq and Chen, Jiajia and Shi, Yingxiao and Glettig, Marc and Feng, Catherine H and Frederick, Dennie T and Freeman, Samuel and Holovatska, Marta M and Manos, Michael P and Zimmer, Lisa and Rösch, Alexander and Zaremba, Anne and Livingstone, Elisabeth and Jameson, Jacob C and Saghafian, Soroush and Lee, Andrew and Zhao, Karena and Morris, Luc G T and Reardon, Brendan and Park, Jihye and Elmarakeby, Haitham A and Schilling, Bastian and Giobbie-Hurder, Anita and Vokes, Natalie I and Buchbinder, Elizabeth I and Flaherty, Keith T and Haq, Rizwan and Wu, Catherine J and Boland, Genevieve M and Hodi, F Stephen and Van Allen, Eliezer M and Schadendorf, Dirk and Liu, David},
  title = {Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma},
  journal = {Science Advances},
  year = {2024},
  volume = {10},
  number = {48},
  doi = {10.1126/sciadv.adp4670}
}
Kostenlos starten →